CR11837A - Inmunoglobulinas con dominio variable dual y usos de la misma - Google Patents
Inmunoglobulinas con dominio variable dual y usos de la mismaInfo
- Publication number
- CR11837A CR11837A CR11837A CR11837A CR11837A CR 11837 A CR11837 A CR 11837A CR 11837 A CR11837 A CR 11837A CR 11837 A CR11837 A CR 11837A CR 11837 A CR11837 A CR 11837A
- Authority
- CR
- Costa Rica
- Prior art keywords
- immunoglobulins
- same
- variable domain
- dual variable
- multivalent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Proteínas de unión multivalentes y multiespecíficas producidas por ingeniería genética, métodos para elaborarlas y, específicamente, sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13081708P | 2008-06-03 | 2008-06-03 | |
US19717208P | 2008-10-23 | 2008-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11837A true CR11837A (es) | 2011-01-12 |
Family
ID=41398845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11837A CR11837A (es) | 2008-06-03 | 2010-12-09 | Inmunoglobulinas con dominio variable dual y usos de la misma |
Country Status (25)
Country | Link |
---|---|
US (3) | US9035027B2 (es) |
EP (2) | EP3002299A1 (es) |
JP (1) | JP2011523853A (es) |
KR (1) | KR20110016958A (es) |
CN (1) | CN102112495A (es) |
AR (1) | AR072001A1 (es) |
AU (1) | AU2009256250B2 (es) |
BR (1) | BRPI0913406A2 (es) |
CA (1) | CA2726087A1 (es) |
CL (1) | CL2010001427A1 (es) |
CO (1) | CO6331347A2 (es) |
CR (1) | CR11837A (es) |
DO (1) | DOP2010000368A (es) |
EC (1) | ECSP10010644A (es) |
IL (1) | IL209529A0 (es) |
MX (1) | MX2010013239A (es) |
NO (1) | NO20101692A1 (es) |
NZ (1) | NZ589434A (es) |
PE (1) | PE20100092A1 (es) |
RU (1) | RU2010153580A (es) |
SG (1) | SG191639A1 (es) |
TW (1) | TW201008580A (es) |
UY (1) | UY31862A (es) |
WO (1) | WO2009149189A2 (es) |
ZA (1) | ZA201008560B (es) |
Families Citing this family (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1133558E (pt) | 1998-11-27 | 2007-01-31 | Ucb Sa | Composições e métodos para aumentar a mineralização óssea |
JP4986370B2 (ja) | 2000-12-22 | 2012-07-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Rgmおよびそのモジュレーターの用途 |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
JP2009510002A (ja) | 2005-09-30 | 2009-03-12 | アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用 |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN102112494A (zh) | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
KR20110031369A (ko) * | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도 |
US20100041133A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US20110070154A1 (en) * | 2008-08-13 | 2011-03-24 | Hyde Roderick A | Artificial cells |
US20100040546A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US8211656B2 (en) * | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
US20100042072A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
WO2010097386A1 (en) * | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
EP2401298A1 (en) * | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
RU2015132478A (ru) | 2009-03-05 | 2015-12-10 | Эббви Инк. | Связывающие il-17 белки |
WO2010115553A1 (en) * | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-2/anti-c-met antibodies |
CN102741288B (zh) | 2009-08-29 | 2015-08-19 | Abbvie公司 | 治疗用dll4结合蛋白 |
JP2013503607A (ja) | 2009-09-01 | 2013-02-04 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
US9493578B2 (en) * | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
AR078651A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011068927A2 (en) * | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
EP2510001B1 (en) | 2009-12-08 | 2015-12-02 | AbbVie Deutschland GmbH & Co KG | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
RU2016146198A (ru) * | 2010-03-02 | 2018-12-19 | Эббви Инк. | Терапевтические dll4-связывающие белки |
US20110223176A1 (en) * | 2010-03-11 | 2011-09-15 | Abbott Laboratories | Basigin binding proteins |
PE20130528A1 (es) | 2010-04-07 | 2013-05-26 | Abbvie Inc | PROTEINAS QUE SE UNEN AL TNF-alfa |
KR101930964B1 (ko) * | 2010-04-20 | 2018-12-19 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
CN102946903B (zh) | 2010-05-14 | 2014-11-26 | 安进公司 | 高浓度抗体制剂 |
ES2635594T3 (es) | 2010-05-14 | 2017-10-04 | Abbvie Inc. | Proteínas de unión a IL-1 |
AU2016222339B2 (en) * | 2010-05-14 | 2017-11-23 | Abbvie Inc. | IL-1 binding proteins |
KR20130043168A (ko) * | 2010-06-24 | 2013-04-29 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
DK3029066T3 (da) | 2010-07-29 | 2019-05-20 | Xencor Inc | Antistoffer med modificerede isoelektriske punkter |
NZ607480A (en) * | 2010-08-03 | 2014-10-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
AU2014246410B2 (en) * | 2010-08-03 | 2016-06-16 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP2608803A4 (en) * | 2010-08-26 | 2014-01-15 | Abbvie Inc | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
KR20130118892A (ko) * | 2010-11-02 | 2013-10-30 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
AU2014259523B2 (en) * | 2010-11-05 | 2016-02-04 | Novartis Ag | Methods of treating psoriatic arthritis using IL-17 antagonists |
ES2733712T3 (es) | 2010-11-05 | 2019-12-02 | Novartis Ag | Métodos para tratar la espondilitis anquilosante utilizando anticuerpos anti-IL-17 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US8911734B2 (en) | 2010-12-01 | 2014-12-16 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
WO2012121775A2 (en) * | 2010-12-21 | 2012-09-13 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
EP2663579B1 (en) | 2011-01-14 | 2017-04-26 | The Regents of the University of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
RU2563830C2 (ru) * | 2011-02-08 | 2015-09-20 | Эббви Инк. | Лечение остеоартрита и боли |
CA2828000A1 (en) * | 2011-03-01 | 2012-09-07 | Amgen Inc. | Bispecific binding agents |
JP5972915B2 (ja) | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Fc変異体 |
CA2830538C (en) | 2011-03-25 | 2020-05-12 | Amgen Inc. | Anti - sclerostin antibody crystals and formulations thereof |
JP6152090B2 (ja) | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 視神経脊髄炎を処置するための組成物および方法 |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US20140255405A1 (en) * | 2011-05-27 | 2014-09-11 | Dutalys | Removal of Monomeric Targets |
EP2739311B9 (en) | 2011-08-04 | 2018-09-19 | Amgen Inc. | Method for treating bone gap defects |
BR112014004168A2 (pt) * | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
EP2771361A1 (en) * | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Bispecific immunobinders directed against tnf and il-17 |
WO2013063114A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against tnf |
TW201323440A (zh) * | 2011-10-24 | 2013-06-16 | Abbvie Inc | 抗骨硬化素(sclerostin)之免疫結合物 |
EA032985B1 (ru) | 2011-12-21 | 2019-08-30 | Амген Инк. | Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc |
SG11201403718YA (en) | 2011-12-28 | 2014-07-30 | Amgen Inc | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
EP2915818A3 (en) | 2011-12-30 | 2015-11-11 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
PL2807192T3 (pl) | 2012-01-27 | 2019-02-28 | Abbvie Deutschland | Kompozycja oraz sposób diagnostyki i leczenia chorób związanych ze zwyrodnieniem neurytów |
RU2620563C2 (ru) * | 2012-02-01 | 2017-05-26 | Ф. Хоффманн-Ля Рош Аг | Способ детекции партнера по связыванию мультиспецифического связывающего агента |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9605058B2 (en) | 2012-05-01 | 2017-03-28 | Glaxosmithkline Llc | Antibodies against the CXC-ELR family of chemokines |
KR101525919B1 (ko) * | 2012-05-11 | 2015-06-03 | 가톨릭대학교 산학협력단 | 자가면역 질환 예방 및 치료를 위한 tnfr2를 기반으로 하는 이중 항체 |
US9708401B2 (en) | 2012-05-22 | 2017-07-18 | Bristol-Myers Squibb Company | IL-17A/F cross-reactive monoclonal antibodies and methods of using the same |
WO2013184200A1 (en) * | 2012-06-05 | 2013-12-12 | Msm Protein Technologies | Human monoclonal antibodies against human chemokine receptor ccr7 |
ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
CN104619342A (zh) | 2012-07-05 | 2015-05-13 | Ucb医药有限公司 | 骨疾病的治疗 |
UY34905A (es) | 2012-07-12 | 2014-01-31 | Abbvie Inc | Proteínas de unión a il-1 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
EP2893343B1 (en) | 2012-09-07 | 2019-11-20 | The Governors of the University of Alberta | Methods for diagnosis of inflammatory liver disease |
WO2014055967A2 (en) * | 2012-10-05 | 2014-04-10 | Neotope Biosciences Limited | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition |
US9217042B2 (en) * | 2012-10-23 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Method of reducing MACE in diabetic patients subsequent to stent placement |
SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
EP2914626A2 (en) * | 2012-11-01 | 2015-09-09 | Abbvie Inc. | Stable dual variable domain immunoglobulin protein formulations |
WO2014078502A1 (en) * | 2012-11-16 | 2014-05-22 | Novartis Ag | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
JP2016501881A (ja) | 2012-12-04 | 2016-01-21 | アッヴィ・インコーポレイテッド | 血液脳関門(bbb)を透過する二重特異性結合タンパク質 |
UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
CN103060274B (zh) * | 2012-12-28 | 2013-12-11 | 首都医科大学 | Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用 |
EP2938634A2 (en) * | 2012-12-28 | 2015-11-04 | AbbVie Inc. | Dual specific binding proteins having a receptor sequence |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
MX2015013166A (es) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. |
JP2016517277A (ja) | 2013-03-15 | 2016-06-16 | アッヴィ・インコーポレイテッド | TNFαに対して指向された二重特異的結合タンパク質 |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
CA2906927C (en) | 2013-03-15 | 2021-07-13 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
EP2970484B2 (en) | 2013-03-15 | 2022-09-21 | Amgen Inc. | Heterodimeric bispecific antibodies |
US9416181B2 (en) | 2013-05-06 | 2016-08-16 | Abbvie Inc. | Compositions for cell culture and methods of using the same |
US9506053B2 (en) | 2013-08-01 | 2016-11-29 | Abbvie Inc. | Methods of selecting biologic-producing cell lines by next generation sequencing |
EP3049440B1 (en) | 2013-09-25 | 2020-03-25 | Amgen Inc. | V-c-fc-v-c antibody |
WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
CN105934444A (zh) | 2013-10-06 | 2016-09-07 | 艾伯维公司 | 针对免疫细胞受体和tlr信号传导自身抗原的双重特异性结合蛋白 |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
EP3062818B1 (en) | 2013-11-01 | 2019-09-11 | IBC Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
ES2923641T3 (es) | 2013-12-30 | 2022-09-29 | Epimab Biotherapeutics Inc | Inmunoglobulina con Fabs en tándem y usos de la misma |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
HUE048478T2 (hu) | 2014-02-02 | 2020-08-28 | Medimmune Ltd | NGF antagonista doménból és TNFalfa antagonista doménból álló kiméra protein |
CA2938994A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Inhalable formulations of sodium cromolyn with improved bioavailability |
DK3104854T3 (da) | 2014-02-10 | 2020-05-04 | Respivant Sciences Gmbh | Mast-celle-stabilisatorer til lungesygdomsbehandling |
RU2732226C2 (ru) * | 2014-03-17 | 2020-09-14 | Мицубиси Танабе Фарма Корпорейшн | Конъюгаты антитело-финомер |
MX2016012578A (es) | 2014-03-28 | 2017-04-13 | Xencor Inc | Anticuerpos biespecificos que se unen a cd38 y cd3. |
NO2776305T3 (es) | 2014-04-23 | 2018-01-27 | ||
CN104004080A (zh) * | 2014-06-06 | 2014-08-27 | 首都医科大学 | 靶向于RANKL和TNF-α的人源化抗体及其应用 |
WO2015191934A2 (en) | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US10398765B2 (en) | 2014-07-03 | 2019-09-03 | Yale University | Dickkopf2 (Dkk2) inhibition suppresses tumor formation |
WO2016040880A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
ES2910227T3 (es) | 2014-10-31 | 2022-05-12 | Univ Pennsylvania | Composición y métodos para la estimulación y expansión de células T |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EA037065B1 (ru) | 2014-11-26 | 2021-02-01 | Ксенкор, Инк. | Гетеродимерные антитела, связывающие cd3 и cd38 |
LT3223845T (lt) | 2014-11-26 | 2021-08-25 | Xencor, Inc. | Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20 |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
US10947305B2 (en) | 2015-03-20 | 2021-03-16 | Full Spectrum Genetics, Inc. | Anti-TNFα binding compounds and uses thereof |
WO2016160976A2 (en) | 2015-03-30 | 2016-10-06 | Abbvie Inc. | Monovalent tnf binding proteins |
US10787500B2 (en) | 2015-04-10 | 2020-09-29 | Adimab, Llc | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species |
CA2977321A1 (en) * | 2015-04-29 | 2016-11-03 | Institute For Research In Biomedicine | Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof |
JP6738831B2 (ja) | 2015-05-04 | 2020-08-12 | アポジェニックス アーゲー | 単鎖cd40受容体アゴニストタンパク質 |
AU2016263030A1 (en) * | 2015-05-18 | 2017-10-12 | Eli Lilly And Company | Anti-Dkk-1-anti-RANKL bispecific antibody compounds |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
JP2017057201A (ja) * | 2015-09-16 | 2017-03-23 | 田辺三菱製薬株式会社 | 抗体−フィノマー複合体を含む医薬組成物 |
WO2017068192A1 (en) | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain cd27-receptor agonist proteins |
AU2016341402B2 (en) | 2015-10-23 | 2020-08-27 | Apogenix Ag | Single-chain GITR-receptor agonist proteins |
EP3365366B1 (en) | 2015-10-25 | 2021-07-14 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
WO2017072080A1 (en) | 2015-10-28 | 2017-05-04 | Apogenix Ag | Single-chain tl1a receptor agonist proteins |
KR20180071376A (ko) * | 2015-11-17 | 2018-06-27 | 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 | Pd-l1 항체, 이의 항원-결합 단편 및 이의 약제학적 용도 |
WO2017085693A1 (en) | 2015-11-19 | 2017-05-26 | AbbVie Deutschland GmbH & Co. KG | Reporter gene assay methods for identifying and analyzing multi-specific binding proteins |
KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
BR112018013407A2 (pt) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc | anticorpos e conjugados dos mesmos |
JP7014724B2 (ja) | 2016-02-06 | 2022-02-01 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Fab免疫グロブリンおよびその使用 |
KR102445255B1 (ko) | 2016-03-02 | 2022-09-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 에리불린-기반 항체-약물 콘주게이트 및 사용 방법 |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
PL3443006T3 (pl) | 2016-04-13 | 2024-01-29 | Sanofi | Trójswoiste i/lub triwalentne białka wiążące |
SG11201808911SA (en) * | 2016-04-13 | 2018-11-29 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
US10604586B2 (en) | 2016-05-09 | 2020-03-31 | Industrial Technology Research Institute | Humanized monoclonal antibody and uses thereof |
AU2017285218A1 (en) | 2016-06-14 | 2018-12-06 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
EP4050032A1 (en) | 2016-06-28 | 2022-08-31 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS |
EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS |
SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3618871A4 (en) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
CN110959015B (zh) * | 2017-07-12 | 2023-07-25 | 四川科伦博泰生物医药股份有限公司 | 双特异性重组蛋白 |
MX2020004129A (es) | 2017-10-10 | 2020-08-20 | Sanofi Sa | Anticuerpos anti-cd38 y metodos de uso. |
CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
MA51291A (fr) | 2017-12-19 | 2020-10-28 | Xencor Inc | Protéines de fusion il-2 fc modifiées |
EP3737949A1 (en) | 2018-01-12 | 2020-11-18 | Genzyme Corporation | Methods for the quantitation of polypeptides |
CA3090177A1 (en) | 2018-02-16 | 2019-08-22 | Abbvie Inc. | Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers |
AU2019243595A1 (en) | 2018-03-30 | 2020-09-17 | Amgen Inc. | C-terminal antibody variants |
CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
CN112867734A (zh) | 2018-04-18 | 2021-05-28 | Xencor股份有限公司 | 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途 |
JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質 |
MA52504A (fr) | 2018-04-30 | 2021-04-28 | Takeda Pharmaceuticals Co | Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations |
CA3115096A1 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
CA3115679A1 (en) | 2018-10-09 | 2020-04-16 | Sanofi | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection |
US11472890B2 (en) | 2019-03-01 | 2022-10-18 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
KR102323342B1 (ko) * | 2019-04-26 | 2021-11-08 | 주식회사 와이바이오로직스 | IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체 |
WO2020251316A1 (ko) * | 2019-06-14 | 2020-12-17 | 에이비엘바이오 주식회사 | α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도 |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
JP2020162622A (ja) * | 2020-06-25 | 2020-10-08 | インスティテュート フォー リサーチ イン バイオメディシン | 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用 |
EP4200332A1 (en) | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Cd3及びgpc3に結合するヘテロ二量体抗体 |
CN117285643A (zh) * | 2022-06-16 | 2023-12-26 | 清华大学 | 一种相变调节套件及其用途 |
Family Cites Families (399)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2128208A (en) | 1937-02-27 | 1938-08-23 | Du Pont | Alkoxy derivatives of methacrylic acid esters and method of producing them |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
DE3587814T2 (de) | 1985-03-30 | 1994-11-10 | Marc Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE111083T1 (de) | 1986-10-22 | 1994-09-15 | Abbott Lab | Chemilumineszierende acridinium- und phenantridiniumsalze. |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5241070A (en) | 1988-09-26 | 1993-08-31 | Ciba Corning Diagnostics Corp. | Nucleophilic polysubstituted aryl acridinium esters and uses thereof |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
SE462454B (sv) | 1988-11-10 | 1990-06-25 | Pharmacia Ab | Maetyta foer anvaendning i biosensorer |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
CA2057923A1 (en) | 1989-05-16 | 1990-11-17 | William D. Huse | Co-expression of heteromeric receptors |
AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
WO1991006287A1 (en) | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
CA2083694A1 (en) | 1990-05-25 | 1991-11-26 | Jenny E. Petering | Marker for yeast strain identification |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
CA2048302A1 (en) | 1990-08-15 | 1992-02-16 | Victoria P. Meucci | Solubilization reagent for biological test samples |
US5135875A (en) | 1990-08-15 | 1992-08-04 | Abbott Laboratories | Protein precipitation reagent |
EP0544809B1 (en) | 1990-08-24 | 1998-12-16 | Ixsys, Inc. | Methods of synthesizing oligonucleotides with random codons |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
AU9166691A (en) | 1990-12-20 | 1992-07-22 | Ixsys, Inc. | Optimization of binding proteins |
ES2287206T3 (es) | 1991-03-01 | 2007-12-16 | Dyax Corporation | Proceso para el desarrollo de mini-proteinas de union. |
US5558864A (en) | 1991-03-06 | 1996-09-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
DE69231828T3 (de) | 1991-03-18 | 2008-06-19 | New York University | Spezifisch gegen menschlichen Tumornekrosefaktor gerichtete monoklonale und chimäre Antikörper |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
IE921169A1 (en) | 1991-04-10 | 1992-10-21 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
TW205553B (es) | 1991-04-25 | 1993-05-11 | Chugai Pharmaceutical Co Ltd | |
EP0583356B1 (en) | 1991-05-01 | 2002-07-31 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5352803A (en) | 1992-03-30 | 1994-10-04 | Abbott Laboratories | 5(6)-methyl substituted fluorescein derivatives |
DE69332988T2 (de) | 1992-03-30 | 2004-05-19 | Abbott Laboratories, Abbott Park | Reagenzien zum Nachweis und zur Quantifizierung von Thyroxin in flüssigen Proben |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
JP3095175B2 (ja) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
AU6132994A (en) | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
EP0659766A1 (en) * | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
CA2178590A1 (en) | 1993-12-10 | 1995-06-15 | Joan D. Tyner | Reagents and methods for the detection of methotrexate |
GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
HU221001B1 (hu) | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
IL109632A (en) | 1994-05-11 | 2007-03-08 | Yeda Res & Dev | Modulators of the function of tnf receptors |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
CA2207961A1 (en) | 1995-01-05 | 1996-07-11 | Robert J. Levy | Surface-modified nanoparticles and method of making and using same |
GB9504344D0 (en) | 1995-03-03 | 1995-04-19 | Unilever Plc | Antibody fragment production |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
CA2218489A1 (en) | 1995-04-21 | 1996-10-24 | Aya Jakobovits | Generation of large genomic dna deletions |
JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク. | 免疫したゼノマウス(XenoMouse)に由来するヒト抗体 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
CA2230494A1 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
NZ536216A (en) * | 1996-02-09 | 2006-08-31 | Abbott Biotech Ltd | Use of an isolated antibody D2E7 for the treatment of a disorder in which TNF(alpha) activity is detrimental |
WO1997032572A2 (en) | 1996-03-04 | 1997-09-12 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
CA2250166A1 (en) | 1996-03-28 | 1997-10-02 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6239259B1 (en) | 1996-04-04 | 2001-05-29 | Unilever Patent Holdings B.V. | Multivalent and multispecific antigen-binding protein |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
KR100643058B1 (ko) | 1996-12-03 | 2006-11-13 | 아브게닉스, 인크. | 복수의 Vн 및 Vк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체 |
JP3884484B2 (ja) | 1997-01-16 | 2007-02-21 | マサチューセッツ インスティチュート オブ テクノロジー | 吸入用粒子の調製 |
ES2373110T3 (es) | 1997-01-21 | 2012-01-31 | The General Hospital Corporation | Selección de proteínas usando fusiones de arn-proteína. |
US7306914B2 (en) | 1997-01-31 | 2007-12-11 | Odyssey Thera Inc. | Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
EP1007967A2 (en) | 1997-08-04 | 2000-06-14 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
US6670453B2 (en) | 1997-10-27 | 2003-12-30 | Unilever Patent Holdings B.V. | Multivalent antigen-binding proteins |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
AU2978899A (en) | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
ES2261589T3 (es) | 1998-05-06 | 2006-11-16 | Genentech, Inc. | Composicion de anticuerpos anti-her2. |
DE69907456T2 (de) | 1998-06-24 | 2004-03-25 | Advanced Inhalation Research, Inc., Cambridge | Grosse poröse partikel ausgestossen von einem inhalator |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US20030215458A1 (en) | 1998-09-30 | 2003-11-20 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
HU229566B1 (en) | 1998-12-23 | 2014-02-28 | Pfizer | Human monoclonal antibodies to ctla-4 |
US8003772B2 (en) | 1999-01-14 | 2011-08-23 | Martek Biosciences Corporation | Chimeric PUFA polyketide synthase systems and uses thereof |
EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
AU4025300A (en) | 1999-03-24 | 2000-10-09 | Packard Bioscience Company | Continuous porous matrix arrays |
AR043274A1 (es) | 1999-03-25 | 2005-07-27 | Abbott Gmbh & Co Kg | Anticuerpos humanos que enlazan a il-12 humana y metodos para producirlos |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
DK2270150T4 (da) | 1999-04-09 | 2019-08-26 | Kyowa Hakko Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle. |
CN1119415C (zh) | 1999-06-04 | 2003-08-27 | 长春迈灵生物工程有限公司 | 抗ca125双功能基因工程抗体的克隆与表达 |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
JP4780633B2 (ja) | 1999-06-25 | 2011-09-28 | イムノゲン インコーポレーティッド | 抗−ErbB抗体−メイタンシノイド複合体を用いた治療方法 |
EP1230269A2 (en) | 1999-11-03 | 2002-08-14 | Maxygen, Inc. | Antibody diversity generation |
CN1461310B (zh) | 2000-02-10 | 2013-06-12 | 雅培制药有限公司 | 结合人白介素-18的抗体及制备和使用方法 |
EP1257296A2 (en) | 2000-02-24 | 2002-11-20 | Genentech, Inc. | Caspase activated prodrugs therapy |
ATE419354T1 (de) | 2000-02-25 | 2009-01-15 | Us Gov Health & Human Serv | Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung |
CA2406993A1 (en) | 2000-03-24 | 2001-09-27 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
CN101289511A (zh) * | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
ATE316137T1 (de) | 2000-05-19 | 2006-02-15 | Scancell Ltd | Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
ES2252261T3 (es) | 2000-06-28 | 2006-05-16 | Glycofi, Inc. | Metodos para producir glicoproteinas modificadas. |
UY26807A1 (es) * | 2000-06-29 | 2002-01-31 | Abbott Lab | Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos |
US20040220388A1 (en) | 2000-06-30 | 2004-11-04 | Nico Mertens | Novel heterodimeric fusion proteins |
US20090081234A1 (en) | 2000-08-07 | 2009-03-26 | George Heavner | Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions |
GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US20030157643A1 (en) | 2000-08-24 | 2003-08-21 | Almond Brian D | Synthetic nucleic acids from aquatic species |
MXPA00009407A (es) | 2000-09-26 | 2004-12-08 | Mexicano Inst Petrol | Procedimiento para la preparacion de un catalizador monometalico de tipo zeolitico para la obtencion de gasolinas de alto octando mediante reformacion de naftas. |
EP1343820A4 (en) | 2000-10-13 | 2005-09-14 | Uab Research Foundation | ANTI-EPIDERMIC GROWTH FACTOR RECEPTOR SINGLE CHAIN ANTIBODY |
EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
US7601692B2 (en) | 2000-11-28 | 2009-10-13 | Compugen Ltd. | MCP-1 splice variants and methods of using same |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6818392B2 (en) | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
AU2002256971B2 (en) | 2000-12-28 | 2008-04-03 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
ATE464322T1 (de) | 2001-01-05 | 2010-04-15 | Pfizer | Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i |
US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
WO2002097048A2 (en) | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
MXPA03010911A (es) | 2001-05-30 | 2004-02-17 | Genentech Inc | Anticuerpos contra ngf para el tratamiento de varios desordenes. |
IL159225A0 (en) | 2001-06-13 | 2004-06-01 | Genmab As | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
WO2003011911A1 (en) | 2001-07-31 | 2003-02-13 | Ono Pharmaceutical Co., Ltd. | Substance specific to pd-1 |
CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
PL369446A1 (en) | 2001-09-25 | 2005-04-18 | Immuno-Biological Laboratories Co, Ltd. | Recombinant anti-osteopontin antibody and use thereof |
ES2327905T3 (es) | 2001-10-01 | 2009-11-05 | Dyax Corp. | Vectores de presentacion eucariotas multi-cadena y usos de los mismos. |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
WO2003039486A2 (en) | 2001-11-09 | 2003-05-15 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
WO2004039826A1 (en) | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
WO2003062375A2 (en) | 2001-12-19 | 2003-07-31 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
WO2003066662A2 (en) | 2002-02-05 | 2003-08-14 | Genentech, Inc. | Protein purification |
MXPA04007583A (es) | 2002-02-11 | 2005-04-25 | Genentech Inc | Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno. |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
EP1499352A4 (en) | 2002-04-12 | 2006-10-11 | Medimmune Inc | ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES |
EP1495055B1 (en) | 2002-04-18 | 2013-08-14 | Genencor International, Inc. | Production of functional antibodies in filamentous fungi |
US7323553B2 (en) | 2002-04-26 | 2008-01-29 | Genentech, Inc. | Non-affinity purification of proteins |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
JP4335130B2 (ja) | 2002-04-30 | 2009-09-30 | 協和発酵キリン株式会社 | ヒトインスリン様成長因子に対する抗体 |
US7714189B2 (en) | 2002-05-03 | 2010-05-11 | Monsanto Technology Llc | High tryptophan maize |
EP2316922B1 (en) | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
ATE514717T1 (de) | 2002-07-18 | 2011-07-15 | Merus B V | Rekombinante produktion von antikörpermischungen |
US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
NZ542784A (en) | 2002-08-19 | 2008-07-31 | Astrazeneca Ab | Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof |
EP1543038B2 (en) | 2002-09-11 | 2020-08-05 | Genentech, Inc. | Protein purification |
JP4315907B2 (ja) | 2002-11-22 | 2009-08-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | マラリア原虫のgpiの生合成を阻害する化合物をスクリーニングする方法 |
CN100434440C (zh) | 2002-12-02 | 2008-11-19 | 阿布格尼克斯公司 | 针对肿瘤坏死因子的抗体及其用途 |
ES2347241T3 (es) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | Variantes de inmunoglobulina y sus utilizaciones. |
ATE553128T1 (de) | 2002-12-24 | 2012-04-15 | Rinat Neuroscience Corp | Anti-ngf-antikörper und verfahren zu ihrer verwendung |
EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
DK2163643T3 (en) | 2003-03-05 | 2015-03-23 | Halozyme Inc | Soluble hyaluronidaseglycoprotein (sHASEGP), process for preparing the same, pharmaceutical compositions and uses thereof covered |
CA2524305C (en) | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
CA2524707A1 (en) | 2003-05-14 | 2004-12-02 | Dow Corning Corporation | Repeat sequence protein polymer active agent conjugates, methods and uses |
US20070104722A1 (en) | 2003-05-15 | 2007-05-10 | Iogenetics | Targeted biocides |
EP1629012B1 (en) | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
MEP31408A (en) | 2003-07-18 | 2010-10-10 | Abgenix Inc | Specific binding agents to hepatocyte growth factor |
EP3095793B1 (en) | 2003-07-28 | 2020-03-25 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
US20050026881A1 (en) | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
JP2007528723A (ja) | 2003-08-22 | 2007-10-18 | メディミューン,インコーポレーテッド | 抗体のヒト化 |
CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US20050095246A1 (en) | 2003-10-24 | 2005-05-05 | Medtronic, Inc. | Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
US7754500B2 (en) | 2003-11-21 | 2010-07-13 | Anp Technologies, Inc. | Asymmetrically branched polymer conjugates and microarray assays |
EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
JP2007517504A (ja) | 2003-12-09 | 2007-07-05 | ベントリア バイオサイエンス | 融合担体として種子貯蔵蛋白を利用する植物種子中の融合ポリペプチドの高水準発現 |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
US7297541B2 (en) | 2004-01-26 | 2007-11-20 | Monsanto Technology Llc | Genes encoding 4-hydroxyphenylpyruvate dioxygenase (HPPD) enzymes for plant metabolic engineering |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
AU2005249360B2 (en) | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
AU2005233387B2 (en) | 2004-04-15 | 2011-05-26 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
ATE537189T1 (de) | 2004-04-30 | 2011-12-15 | Inst Nat Sante Rech Med | Anti-tfr-antikörper |
WO2005120557A2 (en) | 2004-05-13 | 2005-12-22 | Imclone Systems Incorporated | Inhibition of macrophage-stimulating protein receptor (ron) |
CN101094921A (zh) | 2004-05-19 | 2007-12-26 | 阿格芮维达有限公司 | 表达内含肽修饰蛋白的转基因植物及相关生物药物的生产过程 |
GB0412019D0 (en) | 2004-05-28 | 2004-06-30 | Novartis Ag | Organic compounds |
US7150969B2 (en) | 2004-06-04 | 2006-12-19 | Rosetta Inpharmatics Llc | Alternatively spliced isoform of acetyl-CoA carboxylase 2 (ACC2) |
EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
EP1786837B1 (en) | 2004-08-04 | 2013-05-01 | Amgen Inc., | Antibodies to dkk-1 |
RS51326B (sr) | 2004-08-05 | 2010-12-31 | Genentech Inc. | Humanizovani anti-cmet antagonisti |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
WO2006031370A2 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB0419424D0 (en) | 2004-09-02 | 2004-10-06 | Viragen Scotland Ltd | Transgene optimisation |
SI2322556T1 (sl) | 2004-09-03 | 2016-02-29 | Genentech, Inc. | Humanizirani antagonisti proti beta7 in njihove uporabe |
US20060067931A1 (en) * | 2004-09-25 | 2006-03-30 | Hazel Lum | Receptor for lysophosphatidylcholine in vascular endothelial cells and use thereof |
CA2582683A1 (en) | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian eag1 ion channel protein |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
EP1805320B1 (en) | 2004-10-22 | 2014-09-03 | Amgen Inc. | Methods for refolding of recombinant antibodies |
US20060253100A1 (en) | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1838349A1 (en) | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid beta antibodies for use in improving cognition |
CA2595610C (en) | 2004-12-21 | 2013-03-05 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
US20060162026A1 (en) | 2004-12-23 | 2006-07-20 | Karen Oishi | Expressing TGF-beta proteins in plant plastids |
CA2590164A1 (en) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
AU2006214121B9 (en) | 2005-02-15 | 2013-02-14 | Duke University | Anti-CD19 antibodies and uses in oncology |
AU2006216291B2 (en) | 2005-02-27 | 2011-01-27 | Institute For Antibodies Co., Ltd. | Anti-IgSF4 antibody and utilization of the same |
EP2447281B1 (en) | 2005-03-24 | 2015-12-16 | ThromboGenics N.V. | Novel anti-PLGF antibody |
CN101484182B (zh) | 2005-04-06 | 2014-06-11 | Ibc药品公司 | 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途 |
MX2007013217A (es) | 2005-04-25 | 2008-03-11 | Pfizer | Anticuerpos contra miostatina. |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
WO2006121852A2 (en) | 2005-05-05 | 2006-11-16 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
DK1888113T3 (da) | 2005-05-27 | 2014-09-01 | Biogen Idec Inc | Tweak-bindende antistoffer |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
CN101208429A (zh) | 2005-06-24 | 2008-06-25 | 诺维信公司 | 用于药物用途的脂肪酶 |
PT1896073E (pt) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
DE602006017405D1 (de) | 2005-08-11 | 2010-11-18 | Synthetic Genomics Inc | Verfahren zur in vitro-rekombination |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
KR20140053410A (ko) * | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
AR055137A1 (es) | 2005-08-26 | 2007-08-08 | Glycart Biotechnology Ag | Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada |
US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
CA2862540C (en) | 2005-09-21 | 2018-07-31 | The Regents Of The University Of California | Systems, compositions, and methods for local imaging and treatment of pain |
EP2230256A1 (en) | 2005-09-23 | 2010-09-22 | Walter Reed Army Institute of Research (WRAIR) | Antibodies with simultaneous subsite specificities to protein and lipid epitopes |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
EP1945771A1 (en) | 2005-10-28 | 2008-07-23 | Novo Nordisk A/S | Fusion proteins that bind effector lymphocytes and target cells |
UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
KR101442266B1 (ko) | 2005-11-18 | 2014-11-04 | 그렌마크 파머수티칼스 에스. 아. | 항-알파2 인테그린 항체 및 이의 용도 |
AU2006318580A1 (en) | 2005-11-21 | 2007-05-31 | Merck Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
JP5475994B2 (ja) | 2005-11-30 | 2014-04-16 | アッヴィ・インコーポレイテッド | 抗Aβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。 |
ATE552853T1 (de) | 2005-12-13 | 2012-04-15 | Medimmune Ltd | Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen |
KR101535678B1 (ko) | 2006-01-23 | 2015-07-09 | 조셉 피. 에리코 | 표적 약물 개발의 방법 및 조성물 |
US8377691B2 (en) | 2006-01-26 | 2013-02-19 | Integral Molecular, Inc. | Lipoparticles comprising ion channels, methods of making and using the same |
US8012477B2 (en) | 2006-01-31 | 2011-09-06 | Novartis Ag | Methods of treating multiple myeloma using IL-17 binding molecules |
US20070207171A1 (en) | 2006-03-01 | 2007-09-06 | Cerus Corporation | Engineered listeria and methods of use thereof |
CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
JP2009529920A (ja) | 2006-03-21 | 2009-08-27 | ワイス | Rageの拮抗作用のための方法および組成物 |
AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
AU2007245164A1 (en) | 2006-03-28 | 2007-11-08 | Biogen Idec Ma Inc. | Anti-IGF-IR antibodies and uses thereof |
US20070232556A1 (en) | 2006-03-31 | 2007-10-04 | Montine Thomas J | Methods and compositions for the treatment of neurological diseases and disorders |
EP2010213A4 (en) * | 2006-04-10 | 2010-08-11 | Abbott Biotech Ltd | USE AND COMPOSITIONS FOR THE TREATMENT OF JUVENIL RHEUMATOID ARTHRITIS |
KR20080109093A (ko) | 2006-04-14 | 2008-12-16 | 노파르티스 아게 | 안과 장애 치료를 위한 il-1 항체의 용도 |
AR060487A1 (es) | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
US8173860B2 (en) | 2006-04-21 | 2012-05-08 | Gtc Biotherapeutics, Inc. | Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion |
US20070254338A1 (en) | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
CN101058609B (zh) | 2006-05-26 | 2011-04-13 | 神州细胞工程有限公司 | 人源抗体及其表达 |
BRPI0712223A2 (pt) | 2006-06-02 | 2012-07-10 | Aveo Pharmaceuticals Inc | proteìnas de ligação ao fator de crescimento de hepatócito (hgf) |
CA2654000A1 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
AU2007256617A1 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
CN1884517B (zh) | 2006-06-08 | 2010-06-30 | 武汉禾元生物科技有限公司 | 利用谷物非储藏蛋白为融合载体在胚乳表达多肽的方法及应用 |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
EP2405270B1 (en) | 2006-06-30 | 2013-07-17 | Merck Sharp & Dohme Corp. | IGFBP2-Biomarker |
US20080081379A1 (en) | 2006-07-13 | 2008-04-03 | Sigler Gerald F | Homogeneous double receptor agglutination assay for immunosuppressant drugs |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
US7592156B2 (en) | 2006-07-20 | 2009-09-22 | Wyeth | Synthetic dog/human chimeric C-C chemokine receptor 2B |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
CA2660171C (en) | 2006-08-11 | 2017-05-16 | Monsanto Technology Llc | Production of high tryptophan maize by chloroplast targeted expression of anthranilate synthase |
WO2008022152A2 (en) | 2006-08-14 | 2008-02-21 | Xencor, Inc. | Optimized antibodies that target cd19 |
SG174782A1 (en) | 2006-09-08 | 2011-10-28 | Abbott Lab | Interleukin - 13 binding proteins |
US20080075690A1 (en) | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
MX2009003229A (es) | 2006-09-29 | 2009-06-18 | Oncomed Pharm Inc | Composiciones y metodos para diagnosticar y tratar cancer. |
US20080102475A1 (en) | 2006-10-13 | 2008-05-01 | Zhengyan Kan | Alternatively spliced isoform of phosphodiesterase 4B (PDE4B) |
CA2939806A1 (en) | 2006-11-02 | 2008-05-08 | Genentech, Inc. | Humanized anti-factor d antibodies and uses thereof |
AU2007338734A1 (en) | 2006-12-20 | 2008-07-03 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
PT2129396E (pt) | 2007-02-16 | 2013-11-18 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
BRPI0809042B1 (pt) | 2007-03-22 | 2021-08-31 | Biogen Ma Inc. | Proteína de ligação a cd154 isolada, seu uso, e composição |
US7906293B2 (en) | 2007-04-09 | 2011-03-15 | Abbott Laboratories | Acridinium phenyl esters useful in the analysis of biological |
WO2008131376A2 (en) | 2007-04-23 | 2008-10-30 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
DK2164992T3 (en) | 2007-05-30 | 2016-08-15 | Lpath Inc | COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID |
WO2009003142A1 (en) | 2007-06-27 | 2008-12-31 | The Board Of Trustees Of The Leland, Stanford Junior University | Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease |
CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
MX2010001488A (es) | 2007-08-08 | 2010-03-01 | Abbott Lab | Composiciones y metodos para cristalizar anticuerpos. |
JP5485152B2 (ja) | 2007-08-15 | 2014-05-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 単一特異性および多特異性抗体ならびに使用方法 |
CA2702611A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
AU2008337100B2 (en) | 2007-12-17 | 2013-02-28 | Pfizer Limited | Treatment of interstitial cystitis |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
ES2579231T3 (es) | 2008-01-15 | 2016-08-08 | Abbvie Inc | Vectores de expresión de mamíferos mejorados y usos de los mismos |
US7605603B1 (en) * | 2008-02-29 | 2009-10-20 | Altera Corporation | User-accessible freeze-logic for dynamic power reduction and associated methods |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
CN102089430B (zh) | 2008-05-09 | 2015-02-04 | Abbvie公司 | 针对渐进性糖化终极产物受体(rage)的抗体及其用途 |
CN102112494A (zh) | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
US8741287B2 (en) | 2008-06-18 | 2014-06-03 | Abbott Laboratories | PlGF-1 assay and kits and components thereof |
KR20110031369A (ko) * | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP2310049A4 (en) | 2008-07-08 | 2013-06-26 | Abbvie Inc | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF |
WO2010017103A2 (en) | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
AU2009298499A1 (en) | 2008-09-30 | 2010-04-08 | Abbvie Inc. | Improved method of RNA display |
US20110318319A1 (en) | 2008-11-13 | 2011-12-29 | Old Dominion University | ACTIVATION and AGGREGATION OF HUMAN PLATELETS AND FORMATION OF PLATELET GELS BY NANOSECOND PULSED ELECTRIC FIELDS |
EP2373692A4 (en) | 2008-12-04 | 2013-11-20 | Abbvie Inc | IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE |
RU2015132478A (ru) * | 2009-03-05 | 2015-12-10 | Эббви Инк. | Связывающие il-17 белки |
MX2011011670A (es) | 2009-05-01 | 2011-11-18 | Abbott Lab | Inmunoglobulinas de dominio variable dual y usos de las mismas. |
SG175427A1 (en) | 2009-05-01 | 2011-12-29 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
CN102741288B (zh) | 2009-08-29 | 2015-08-19 | Abbvie公司 | 治疗用dll4结合蛋白 |
JP2013503607A (ja) | 2009-09-01 | 2013-02-04 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
KR20120104542A (ko) | 2009-10-15 | 2012-09-21 | 아보트 러보러터리즈 | Il?1 결합 단백질 |
AR078651A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
RU2016146198A (ru) | 2010-03-02 | 2018-12-19 | Эббви Инк. | Терапевтические dll4-связывающие белки |
ES2635594T3 (es) | 2010-05-14 | 2017-10-04 | Abbvie Inc. | Proteínas de unión a IL-1 |
KR20130043168A (ko) | 2010-06-24 | 2013-04-29 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
NZ607480A (en) | 2010-08-03 | 2014-10-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2608803A4 (en) | 2010-08-26 | 2014-01-15 | Abbvie Inc | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
KR20130118892A (ko) | 2010-11-02 | 2013-10-30 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
UY33707A (es) | 2010-11-04 | 2012-05-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
EP2915818A3 (en) | 2011-12-30 | 2015-11-11 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
CA2862433A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
US20140213772A1 (en) | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
MX2015013166A (es) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. |
JP2016517277A (ja) | 2013-03-15 | 2016-06-16 | アッヴィ・インコーポレイテッド | TNFαに対して指向された二重特異的結合タンパク質 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2009
- 2009-06-03 EP EP15189272.6A patent/EP3002299A1/en not_active Withdrawn
- 2009-06-03 MX MX2010013239A patent/MX2010013239A/es active IP Right Grant
- 2009-06-03 EP EP09759348A patent/EP2297209A4/en not_active Withdrawn
- 2009-06-03 NZ NZ589434A patent/NZ589434A/xx not_active IP Right Cessation
- 2009-06-03 JP JP2011512617A patent/JP2011523853A/ja not_active Ceased
- 2009-06-03 TW TW098118450A patent/TW201008580A/zh unknown
- 2009-06-03 US US12/477,711 patent/US9035027B2/en active Active
- 2009-06-03 KR KR1020107029457A patent/KR20110016958A/ko not_active Application Discontinuation
- 2009-06-03 AR ARP090101994A patent/AR072001A1/es not_active Application Discontinuation
- 2009-06-03 BR BRPI0913406A patent/BRPI0913406A2/pt not_active IP Right Cessation
- 2009-06-03 WO PCT/US2009/046137 patent/WO2009149189A2/en active Application Filing
- 2009-06-03 CA CA2726087A patent/CA2726087A1/en not_active Abandoned
- 2009-06-03 AU AU2009256250A patent/AU2009256250B2/en not_active Ceased
- 2009-06-03 SG SG2013042916A patent/SG191639A1/en unknown
- 2009-06-03 UY UY0001031862A patent/UY31862A/es not_active Application Discontinuation
- 2009-06-03 RU RU2010153580/10A patent/RU2010153580A/ru not_active Application Discontinuation
- 2009-06-03 PE PE2009000768A patent/PE20100092A1/es not_active Application Discontinuation
- 2009-06-03 CN CN2009801297830A patent/CN102112495A/zh active Pending
-
2010
- 2010-11-23 IL IL209529A patent/IL209529A0/en unknown
- 2010-11-29 ZA ZA2010/08560A patent/ZA201008560B/en unknown
- 2010-11-29 EC EC2010010644A patent/ECSP10010644A/es unknown
- 2010-11-30 CO CO10150956A patent/CO6331347A2/es not_active Application Discontinuation
- 2010-11-30 DO DO2010000368A patent/DOP2010000368A/es unknown
- 2010-12-03 NO NO20101692A patent/NO20101692A1/no not_active Application Discontinuation
- 2010-12-09 CR CR11837A patent/CR11837A/es not_active Application Discontinuation
- 2010-12-10 CL CL2010001427A patent/CL2010001427A1/es unknown
-
2014
- 2014-04-08 US US14/248,223 patent/US20140335014A1/en not_active Abandoned
-
2015
- 2015-04-15 US US14/687,392 patent/US20150315283A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
UY31862A (es) | 2010-01-05 |
DOP2010000368A (es) | 2011-02-15 |
TW201008580A (en) | 2010-03-01 |
US20150315283A1 (en) | 2015-11-05 |
ZA201008560B (en) | 2014-05-28 |
SG191639A1 (en) | 2013-07-31 |
IL209529A0 (en) | 2011-01-31 |
NZ589434A (en) | 2012-11-30 |
EP2297209A2 (en) | 2011-03-23 |
ECSP10010644A (es) | 2011-02-28 |
NO20101692A1 (no) | 2011-03-03 |
AU2009256250B2 (en) | 2013-05-30 |
KR20110016958A (ko) | 2011-02-18 |
CA2726087A1 (en) | 2009-12-10 |
EP2297209A4 (en) | 2012-08-01 |
CN102112495A (zh) | 2011-06-29 |
CL2010001427A1 (es) | 2011-07-15 |
RU2010153580A (ru) | 2012-07-20 |
JP2011523853A (ja) | 2011-08-25 |
US9035027B2 (en) | 2015-05-19 |
MX2010013239A (es) | 2011-02-24 |
PE20100092A1 (es) | 2010-03-12 |
AR072001A1 (es) | 2010-07-28 |
US20140335014A1 (en) | 2014-11-13 |
US20090311253A1 (en) | 2009-12-17 |
CO6331347A2 (es) | 2011-10-20 |
BRPI0913406A2 (pt) | 2018-01-09 |
EP3002299A1 (en) | 2016-04-06 |
WO2009149189A2 (en) | 2009-12-10 |
WO2009149189A3 (en) | 2010-03-04 |
AU2009256250A1 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11837A (es) | Inmunoglobulinas con dominio variable dual y usos de la misma | |
CR20110631A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
CR20120154A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
UY31861A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
ECSP12011922A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
CO6690781A2 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
ECSP13012648A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
DOP2010000325A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
CR20120267A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
UY33707A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
DOP2013000025A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
CR20130074A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
ECSP13012402A (es) | Inmunoglobulinas con dominio variable dual y su uso | |
ECSP12011885A (es) | Inmunoglobulinas con dominio variable dual | |
UY33826A (es) | Proteínas de unión con dominios trivariables y sus usos | |
UY32808A (es) | Inmunoglobulinas como dominio variable dual y usos de las mismas | |
ECSP13012523A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
CO6541599A2 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |